Adebrelimab
- Generic Name
- Adebrelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2247114-85-6
- Unique Ingredient Identifier
- 1XBY50W1OX
- Background
Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).
- Indication
用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05942378
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT05753826
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fujian, China
Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 129
- Registration Number
- NCT05444088
- Locations
- 🇨🇳
Anhui Provincial Hospital Ethics Commitee, Hefei, Anhui, China
Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 400
- Registration Number
- NCT04516681
- Locations
- 🇨🇳
Fudan university shanghai cancer center, Shanhai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath